{"id":23825,"date":"2022-05-05T14:17:29","date_gmt":"2022-05-05T13:17:29","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=23825"},"modified":"2022-05-05T14:17:32","modified_gmt":"2022-05-05T13:17:32","slug":"bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/","title":{"rendered":"BCG &#038;Wellcome report: Understanding the antibiotic manufacturing ecosystem"},"content":{"rendered":"\n<p><a href=\"https:\/\/cms.wellcome.org\/sites\/default\/files\/2022-04\/understanding-the-antibiotic-manufacturing-ecosystem-2022.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Download report <\/a> <\/p>\n\n\n\n<p>The analysis focused on active pharmaceutical ingredient (API) manufacturing, and to a lesser extent intermediate manufacturing (stage prior to API manufacturing), as these are often the bottlenecks of the supply chain.<br>Additionally, the API stage poses the highest risk of antibiotic discharge into the environment during the manufacturing process.<\/p>\n\n\n\n<p>Overall, there is limited vertical integration across the antibiotic supply chain, with various manufacturing stages often outsourced. This means an antibiotic consumed or used by a patient or animal will have involved manufacturing efforts by multiple different companies.<\/p>\n\n\n\n<p>Additionally, the antibiotic supply chain is significantly reliant on China and India, particularly at the API and intermediate stages:<br>\u2022 For a representative shortlist of 40 antibiotic APIs, close to 70% of the manufacturing sites are found in these two countries: 35% in India and 34% in China:<br>\u2022 China is the largest exporter of antibiotic APIs in the world, with 74 kilotonnes exported in 2020, accounting for 71% of global inter-regions exports (across all antibiotic APIs)<br>\u2022 Intermediate manufacturing is particularly reliant on China, with more than 65% of the sites manufacturing four key intermediates based in China.<\/p>\n\n\n\n<p>A representative shortlist of 40 antibiotics was used to further characterise the impact of environmental measures on the antibiotic supply chain. Here, three antibiotic supply chain archetypes in terms of resilience of the API stage to new environmental regulation were identified. These archetypes may equally be relevant to other forms of change or disruption in the supply chain.<\/p>\n\n\n\n<p>Supply chains resilient to new environmental regulation due to a high number of API manufacturing sites: mainly includes first-line generics with high demand. These have relatively low margins, but a high number of manufacturing sites \u2013 often geographically spread \u2013 which can reinforce supply if any sites are disrupted.<\/p>\n\n\n\n<p>Supply chains with limited disruption risk from new environmental regulation due to high API margins: includes patented molecules, which have a limited number of manufacturing sites but high margins which gives manufacturers greater ability to absorb change.<\/p>\n\n\n\n<p>Supply chains exposed to heightened risk from new environmental regulation due to low margins and limited number of API manufacturing sites: includes mainly antibiotics treating niche indications and last resort generics. These have low-to-medium margins and a small number of often geographically concentrated manufacturing sites which leaves manufacturers less able to absorb change and the supply more open to disruption if any sites stop manufacturing.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>To better understand the impact of regulation both at a macro level and on select individual supply chains, two plausible environmental regulatory options that have been linked to current avenues of interest by policy makers for implementation were characterised. The two options differ in concentration limits, measuring location, and monitoring method:<br>\u2013 Option A: based on the AMR Industry Alliance Manufacturing Framework guidelines, entails antibiotic concentrations to be measured in the \u201cmixing zone\u201d after dilution (e.g., river water) and quantified via mass balance (whereby one calculates the amount of lost material by accounting for material entering and leaving the system) against set concentration limits.<\/p>\n\n\n\n<p>\u2013 Option B: based on the Indian government\u2019s draft 2020 regulation which was subsequently dropped, is overall more<br>stringent than Option A. It has lower (i.e. stricter) antibiotic concentration limits than Option A and requires analytical monitoring (e.g. via mass spectrometry) of the antibiotic levels in the effluent wastewater before dilution.<\/p>\n\n\n\n<p><a href=\"https:\/\/cms.wellcome.org\/sites\/default\/files\/2022-04\/understanding-the-antibiotic-manufacturing-ecosystem-2022.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Further reading<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Download report The analysis focused on active pharmaceutical ingredient (API) manufacturing, and to a lesser extent intermediate manufacturing (stage prior to API manufacturing), as these are often the bottlenecks of the supply chain.Additionally, the API stage poses the highest risk of antibiotic discharge into the environment during the manufacturing process. Overall, there is limited vertical [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":23831,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[37],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BCG &amp;Wellcome report: Understanding the antibiotic manufacturing ecosystem - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BCG &amp;Wellcome report: Understanding the antibiotic manufacturing ecosystem - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-05T13:17:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-05T13:17:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Medicine-drug.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"454\" \/>\n\t<meta property=\"og:image:height\" content=\"493\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"BCG &#038;Wellcome report: Understanding the antibiotic manufacturing ecosystem\",\"datePublished\":\"2022-05-05T13:17:29+00:00\",\"dateModified\":\"2022-05-05T13:17:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/\"},\"wordCount\":548,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Medicine-drug.jpg\",\"articleSection\":[\"Bilans, rapports et recommandations\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/\",\"name\":\"BCG &Wellcome report: Understanding the antibiotic manufacturing ecosystem - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Medicine-drug.jpg\",\"datePublished\":\"2022-05-05T13:17:29+00:00\",\"dateModified\":\"2022-05-05T13:17:32+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Medicine-drug.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Medicine-drug.jpg\",\"width\":454,\"height\":493,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Bilans, rapports et recommandations\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"BCG &Wellcome report: Understanding the antibiotic manufacturing ecosystem\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BCG &Wellcome report: Understanding the antibiotic manufacturing ecosystem - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/","og_locale":"fr_FR","og_type":"article","og_title":"BCG &Wellcome report: Understanding the antibiotic manufacturing ecosystem - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2022-05-05T13:17:29+00:00","article_modified_time":"2022-05-05T13:17:32+00:00","og_image":[{"width":454,"height":493,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Medicine-drug.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"BCG &#038;Wellcome report: Understanding the antibiotic manufacturing ecosystem","datePublished":"2022-05-05T13:17:29+00:00","dateModified":"2022-05-05T13:17:32+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/"},"wordCount":548,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Medicine-drug.jpg","articleSection":["Bilans, rapports et recommandations"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/","name":"BCG &Wellcome report: Understanding the antibiotic manufacturing ecosystem - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Medicine-drug.jpg","datePublished":"2022-05-05T13:17:29+00:00","dateModified":"2022-05-05T13:17:32+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Medicine-drug.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Medicine-drug.jpg","width":454,"height":493,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/bcg-wellcome-report-understanding-the-antibiotic-manufacturing-ecosystem\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Bilans, rapports et recommandations","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/"},{"@type":"ListItem","position":4,"name":"BCG &Wellcome report: Understanding the antibiotic manufacturing ecosystem"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-10 22:04:05","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/23825"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=23825"}],"version-history":[{"count":16,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/23825\/revisions"}],"predecessor-version":[{"id":23861,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/23825\/revisions\/23861"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/23831"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=23825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=23825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=23825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}